CMS Sticks To Its Guns: Amyvid Alzheimer’s Screening Not Covered In Medicare Population
This article was originally published in RPM Report
Executive Summary
The final coverage decision for Lilly’s Amyvid sticks with the proposal to limit payment to use in clinical trials. That is a setback for Lilly, but reinforces the Medicare agency’s commitment to the Coverage with Evidence Development pathway.